SANTA CLARA, Calif., June 28, 2017 /PRNewswire/ -- Non-invasive liquid biopsy assay testing is poised to transform the
"New developments in NGS and proteomics are allowing measurement of multiple biomarkers in blood and other body fluids with increased sensitivity and specificity for use in screening and management for each cancer type," said Transformational Health Industry Analyst Divyaa Ravishankar. "Another prominent trend is the heavy investment of pharmaceutical companies into liquid biopsy startup companies to develop companion diagnostics products. Insurance companies are motivating preventive medicine with cancer screening included in wellness programs offered through employer insurance to prevent more expensive chronic disease."
US Oncology Diagnostics Market, Forecast to 2021, recent research from Frost & Sullivan's Life Sciences Growth Partnership Service program, examines the U.S. oncology diagnostics market and identifies growth segments, trends driving adoption, and strategic measures taken by market majors such as Abbott, Roche, Siemens Healthineers, Qiagen, Beckman Coulter, Ortho Clinical Diagnostics, Genomic Health and Myriad. Cancer types covered include breast cancer, ovarian cancer, cervical cancer, colorectal cancer, prostate cancer, and lung cancer.
To know more about Frost & Sullivan's research and to sign up for our Growth Strategy Dialogue, a complimentary one-hour interactive session with Frost & Sullivan's thought leaders, please click here.
Developments and trends driving growth in the U.S. oncology diagnostics market include:
"In the future, cancer biomarker tests will be multiplexed and consist of multiple biomarker types and hereditary testing will be used to identify high-risk population for early signs of cancer," noted Ravishankar. "Micro ribonucleic acid (miRNA), small, single-stranded, non-coding RNA molecules that bind target Messenger RNA (mRNA) to prevent protein production will be used to regulate key cancer related pathways involved in cancer drug therapy resistance."
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community.
US Oncology Diagnostics Market, Forecast to 2021K165-55
Contact:Mariana FernandezCorporate Communications North AmericaP: +54 11 4778 3540F: +54 11 4777 0071E: Mariana.Fernandez@frost.com
twitter: @FS_HealthcareLinkedIn: Transform Health
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cancer-moonshot-initiatives-unlock-technology-innovations-surrounding-algorithms-for-predictive-diagnosis-300481109.html
SOURCE Frost & Sullivan
Subscribe to our Free Newsletters!
Our kitchen and food has the best medicinal properties to fight stress. These are the top 10 foods ...
Unripe green papaya fruit is a rich source of important nutrients including vitamins, proteins, & ...
Selfie obsession or selfitis, an obsessive, uncontrollable urge to post self-taken photographs on ...View All